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Background: Mitoxantrone (MX) has been used as second line therapy for aggressive multiple sclerosis (MS).
Potential cardiotoxic effects of MX limit its use; a cumulative dose of up to 100 mg/m2, has been long considered
relatively safe. We calculated the frequency of cardiac side effects in MS patients treated with MX.
Methods: We performed a cohort study including all MS patients treated with MX at the Neurological Department
of the University Hospital of Palermo, Italy. Two hundred-sixty-four MS patients diagnosed according to validated
criteria were included and followed-up until the end of September 2010. Patients were treated with MX as a
second line therapy if they had no previous heart diseases determined by clinical evaluation, electrocardiography,
and echocardiography. Treatment administration was made at a monthly dose of 8 mg/m2 for the first three
months and at a dose of 12 mg/m2 every three months. Echocardiography was routinely performed every six
months. Treatment was stopped before reaching the final dose if signs had appeared of impaired heart function,
confirmed left ventricular ejection fraction reduction lower to 50%, or a confirmed reduction of more than 10%
with respect to the first examination.
Results: Heart involvement was observed in 12.4% of treated individuals, and symptomatic congestive heart failure
occurred in 2.7% of the cohort. A patient had a myocardial infarction, and 3.1% showed electrocardiographic
anomalies not present at baseline.
Conclusion: Our study confirms that cardiac adverse events associated with MX are more common than
previously reported.
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Multiple sclerosis (MS) is a chronic disease of the central
nervous system due to a damage of myelin sheaths and
axons mediated by the immune system and by a neurode-
generative mechanism. MS is one of the major causes of
disability in young people. Its causes are still unknown
although is generally accepted that MS is a complex
autoimmune disorder where genetic and environmental
factors both contribute to the pathogenic mechanisms
directed against myelin and oligodendrocytes of the cen-
tral nervous system. Plaques in MS patients are* Correspondence: paolo.ragonese@unipa.it
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inflammatory cells, demyelination, axonal loss and gliosis,
mainly in the white matter, all along the brain and the
spinal cord [1].
Among treatments used for MS, Mitoxantrone (MX)
has been used as a second line therapy for multiple
sclerosis (MS) [2]. MX is an anthracenedione that
reduces lymphocyte proliferation of B and T cells,
macrophages, and lowers the production of pro-
inflammatory cytokines [3]. Its efficacy in the treatment
of MS was tested in clinical trials and, for this reason,
the drug in 2000 was approved by FDA [4, 5]. Cardio-
toxic effects of MX limit the cumulative lifetime dose in
MS patients to 140 mg/m2. A cumulative dose of no morele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Demographic and clinical characteristics of MS patients
treated with MX
Variable N
Gender (W/M) 264 (158/106)
Mean age at onset (years +/- SD) 48 (10.3)
Disease course
RR 65 (41 D/24 U)
SP 132 (82 D/50 U)
PP 38 (19 D/19 U)
PR 29 (16 D/13 U)
Mean disease duration (years, range) 11,3 (1 – 38)
Mean Follow-up (years +/- SD) 8 (3)
Mean number of MTX (range) 7,5 (1 – 21)
Mean cumulative dose/m2 (range) 70,8 (1 – 139)
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cently (2, 6). More recent observations described higher
frequency than expected of cardiac involvement in people
exposed to MX [6, 7]. Aim of the present study was to es-
timate the frequency of heart involvement in a cohort of
Sicilian MS patients treated with MX.
Methods
We used MX at our department after other treatments
had failed to demonstrate a reduction of relapse fre-
quency or of disability worsening in patients affected by
MS. Before starting MX, patients were first screened for
previous cardiovascular diseases by clinical examination,
electrocardiography, and by transthoracic echocar-
diography. We also considered previous uses of cardio-
toxic or cytotoxic medications, history of heart disease,
current pregnancy or breast-feeding as contraindications
to MX treatment. We planned treatment administration
at a monthly dose of 8 mg/m2 for the first three months,
followed by a dose of 12 mg/m2 every three months up
to a cumulative dose of 140 mg/m2. Transthoracic
echocardiographs were scheduled every two cycles at the
beginning (in the first period when treatment was
administered with a monthly regimen), and then every
6 months. These data were recorded in the clinical
database of MS patients followed at our Department.
Echocardiography was usually performed at the
cardiologic department of our University Hospital. If an
echocardiography, performed by a patient elsewhere for
any reason, showed any kind of changes from baseline,
this was evaluated again at our University Hospital
cardiologic department. Treatment was stopped before
reaching the planned final dose if there were signs of
impaired heart function, confirmed left ventricular
ejection fraction (LVEF) reduction to less than 50%, or a
confirmed reduction of more than 10% with respect to
the first examination. Confirmed modifications of left
ventricular ejection fraction (LVEF) had to be present at
least in two consecutive evaluations. Further cardiologic
evaluations and echocardiographic examinations were
also performed six and twelve months after the last
administration of MX. Reduction or termination of
infusions due to adverse events was left at the physician’s
judgment. Doses of MX were reduced particularly in
case of severe leukopenia, red blood cell or platelet re-
duction, severe infections or other clinically relevant
serological markers modifications. We evaluated the
occurrence of several conditions: symptomatic heart
failure, changes at electrocardiography or echocardiography
suggesting a possible initial heart failure, arrhythmias, valve
involvement, pericardial effusion, myocardial infarction. Ac-
cording to the Therapeutics and Technology Assessment
Subcommittee of the American Academy of Neurology [2],
we considered two different end points: the occurrence ofsymptomatic congestive heart failure and the frequency of
heart involvement (any type) calculated as the rate of pa-
tients developing one of the above mentioned conditions.
The observation started in 1994 at the time of inclusion of
the first patient for MX treatment while for outcome
measures we considered September 30th 2010 as the end of
follow-up. We also compared echocardiographic parame-
ters in the cohort of MS patients at baseline with two
hundred individuals studied by echocardiography for other
reasons in a similar age group and excluding those who
had a previous known heart disease. This group of people
included mostly individuals evaluated by echocardiography
as a screening procedure to perform agonistic sport
activities. We used t test to compare means, and Χ square
analysis to calculate differences in distribution of LVEF be-
tween MS patients and referent subjects at baseline. We
also calculated the relative risk (RR) with 95% confidence
intervals (CI) and two-sided p values for congestive heart
failure stratifying by age, gender, cumulative dose of MX,
number of MX doses, and disease duration from onset to
MX initiation.
The local ethical committee of our University Hospital
approved the study, and a consensus was obtained from
each patient to be treated with the drug and to be
included in our clinical database.
Results
Patient’s characteristics are described in Table 1. Two
hundred-sixty-four MS patients (158 women, 106 men)
were treated as above described. Mean age at onset of MX
treatment was 48 years old (standard deviation 10.3).
Mean disease duration was 11.3 years (range 1–38) from
onset of symptoms. Sixty-five patients (24.6%) had a
relapsing-remitting (RR) disease course when they started
MX while the remaining 199 (74.8%) had a secondary or
primary progressive disease course with presence of re-
lapses (among them, 21 patients had a primary progressive
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istered (range 1–21); mean cumulative dose of MX was
70.8 (range 1–139) mg/m2 of body surface. Two hundred
consecutive individuals not affected by MS (106 women,
94 men) were examined as reference group. They had a
mean ejection fraction (EF) of 58%, (median: 60, SD: 5.6).
We observed no statistical differences between MS
patients and the non-MS patients at baseline. None of
these subjects had significant clinical or echocardiographic
abnormalities except one who had mild signs of atrial
enlargement and mitral valve insufficiency. MS patients
had mean a follow-up of 8 years since their inclusion in
the study (SD +/- 3). Frequency of any type of cardiac
function involvement was 12.5% (33 patients) in MS
patients. Signs or symptoms of heart dysfunction occurred
within the first two years after the initiation of the treat-
ment in 16 individuals (6%). In eight patients serious
adverse events occurred within the first six months of
treatment, including two deaths (determined in one case
by severe leukopenia and pneumonia). One patient devel-
oped leukaemia while five other patients developed signs
of heart dysfunction. Congestive heart failure occurred in
2.7% of patients (3 men, 4 women). A woman died 8 years
after MX exposure because of severe heart failure whose
onset was attributed to MX treatment (she was considered
also among those patients affected by heart failure). An-
other patient had a myocardial infarction, while 8 (3.1%)
patients showed electrocardiographic abnormalities or
arrhythmias not present at baseline. The remaining had a
sustained LVEF reduction without evident clinical signs of
congestive heart failure. Among other relevant clinical dis-
orders whose onset was considered attributable to MX
treatment, we observed three cases of acute leukaemia
and a death due to a pancreatic cancer. Two other pa-
tients died: one because of a heat shock (after the second
MX course) and one of acute pneumonia (after the fifth
infusion). Table 2, reports the risk rates for the association
between symptomatic heart disease and the considered
variables. Risk for heart involvement (any type) was sig-
nificantly associated with the duration and the dose of the
treatment. On the opposite, sex and MS duration since
onset did not show any association with the probability to
develop a heart disease. We observed an increased risk forTable 2 Association between MX treatment and the occurrence
of symptomatic congestive heart failure
Variable RR (CI)a p
Age 3.57 (0.98 – 19.9) 0.12
Gender 1.05 (0.70 – 2.40) 1
Disease duration 0.8 (0.7 – 1.1) 0.3
Cumulative dose 2.3 (1.54 – 3.66) 0.000003
Number of infusion 2.3 (1.4 – 3.8) 0.0003
aRR = relative risk. CI = 95% confidence intervalsheart disease related to age at treatment initiation
although only close to the statistical significance. Charac-
teristics of patients who developed congestive heart failure
are reported in Table 3.
Discussion
This study confirms previous reports showing frequency
of heart disease higher than previously reported in MS
patients treated with MX [5–8]. We observed a dose and
time related heart toxicity. Rate of heart involvement
was also high considering either symptomatic heart fail-
ure, subclinical toxicity or measuring any type of heart
event. Another recent study performed in France sug-
gested a better safety profile of MX showing [9]. In that
study, nearly 5% of MS patients developed asymptomatic
reduction of LVEF at the end of the five-year follow-up
(compared to nearly 12% in our cohort), and just one
patient over a cohort of about 800, developed acute
heart failure (vs. 2.8% in the present study). Differences
in observed frequencies of MX related heart toxicity
might be determined mostly by the methodology used to
calculate the occurrence of events (length of follow-up,
frequency and number of echocardiography, methods to
assess the reduction of LVEF). The inclusion of symp-
tomatic heart failure only, or to encounter LVEF reduc-
tion is also determinant of course in the calculation of
heart event frequency (i.e. to calculate cardiac disease
rate just by including those individuals who present
clinical sign of heart failure would produce lower rates
compared to studies including as affected by heart dis-
ease also those patients with modification of echocardio-
graphic parameters). There is another major difference
between the two cohorts represented by the proportion
of patients with a RR disease course vs. a progressive
course (in our cohort, it approximates the 25% while in
the French cohort was about the 38%). This is paralleled
by the different age at MX initiation which is higher in
the Sicilian cohort (mean age of 38 years old for the
French study, compare to 48 years for the present
cohort). In our cohort, there seems to be a higher risk
for heart disease among patients who had MX treatment
at an older age although confidence intervals are wide and
do not reach the statistical significance. This would alsoTable 3 Characteristics of heart involvement in MS patients
treated with MTX
Type of heart involvement Percent Number
Heart dysfunction (any type) 12.5 33
Symptomatic heart failure 2.7 7
ECG abnormalities/arrhythmias 3.1 8
Myocardial infarction 0.4 1
Death due to heart failure 0.4 1
Deaths due to other causes (heat shock) 0.4 1
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our cohort although the reported risk is not significant,
probably because of the low number of events. Other ex-
planations for differences in observed results may depend
on the criteria and methodology used in other studies to
define and to assess the presence and the severity of heart
diseases [10, 11]. As already mentioned, the distribution of
clinical phenotypes of MS patients included in the study,
as well as age at initiation of MTX therapy, have to be
considered possible factors determining a modification of
the observed effects when comparing present results with
those from other studies [12]. It has been suggested that
in patients undergoing MX treatment for other diseases
like cancer, prevention from developing heart failure it is
possible to obtain by aerobic exercises, by modification of
treatment regimens, or even by routine use of cardiac pro-
tective agents or liposomal formulations during the treat-
ment [12]. There is no evidence at present, supporting
these suggestions. Moreover, it has not been investigated
if these different approaches (reduced dose or time of
treatment, or even delayed courses) may warrant a better
long-term efficacy particularly among patients like those
affected by MS who have a very long expected survival
time after exposure to the drug. As previously reported,
throughout follow-up time, a small proportion of cases
showed at least a partial reversibility of LVEF reduction
[12, 13]. In the present study, anyway, we reported results
of sustained LVEF reduction in patients who had a mean
follow-up time of eight years and as indicated, the time
elapsed from treatment initiation to the onset of congest-
ive heart failure may go over the duration of treatment
administration. Another important aspect to consider is
that LVEF reduction is only an aspect and an early marker
of cardiomyopathy which is a more complex pathologic
process characterized by a global systolic dysfunction
when left ventricular enlargement is still not clearly evi-
dent [12, 14]. This is of outstanding importance because
other reports have shown that cardiomyopathy in patients
treated with MX can occur early after few infusions when
either clinical symptoms nor LVEF reduction may be
already detected [13–16]. As previously described, cardio-
myopathy may in fact occur early, manifesting with aspe-
cific ST-segment and T-wave abnormalities, or as the late
dose-related heart failure and left ventricular dysfunction
[15, 17]. In our study and in previous observations [2],
myocardial infarctions and arrhythmias had also been
observed and included in the calculation of MX related
toxicity. For these reasons we believe that early signs must
also be accurately searched, as treated patients could later
develop a congestive heart failure and also because recent
studies indicate the possibility of an efficacious early
treatment [15, 16, 18, 19].
Few studies have been performed in Europe reporting
the incidence of heart dysfunction in the generalpopulation with a similar age distribution [17, 20]. Two
studies performed in Italy investigating the frequency of
heart dysfunction in two cohorts of individuals who per-
formed cardiologic evaluations to monitor heart function
in young adult individuals [18–23] showed rates of
hypertrophic cardiomyopathy between 0.07 and 0.7%. In
the group of individuals performing echocardiography
and not affected by MS we considered for comparisons,
we did not observed any difference at baseline with re-
spect to MS patients and, as previously reported, only
one had significant signs of potential heart disease at
echocardiographic examination. A limitation relies any-
way on the fact that we could not obtain a follow-up
examination of referent subjects as those people were
screened only once. Nevertheless, we did not observed
in our MS cohort at baseline any significant heart dis-
ease sign nor significant abnormalities were present at
echocardiography performed before MTX treatment,
since this would have represented an exclusion criteria
for this specific treatment. Finally, we observed several
serious side effects like cancers; in our cohort, we ob-
served in fact three case of leukaemia, one lung cancer,
one gut cancer, and one of the pancreas. This confirms
the need for a strict control of MX related toxicity even
after treatment stopping.
Conclusion
Although the use of MTX in patients with MS has
declined in last years, it still represents an alternative in
selected cases with very aggressive disease. Furthermore,
the debate is still open about the opportunity to adopt
an induction strategy able to exert effects on innate im-
munity, when approaching MS treatment and in this
perspective, other drugs have still to prove to be as
effective as MTX could be. The present study suggest a
significantly increased risk for cardiovascular comor-
bidity and toxicity among MS patients treated with
MTX. Heart involvement seemed to be dependent on
the dose and the duration of MTX exposure but not on
age or disease duration. On the opposite, in the cohort
of MS patients included there were no differences in
echocardiographic parameters at baseline with respect to
another group of individuals not affected by MS.
Although the results of the present study confirm
previous concerns about a broad and prolonged use of
MTX for the treatment of MS, some additional consid-
eration are needed. It has already been suggested that, in
the effort to guarantee MS patients with the best pos-
sible treatment to prevent the accrual of not reversible
disability, particularly for patients with clinical subtypes
that do not have yet valid therapeutic opportunities,
MTX could still represent one the few chances available
[24]. What it is still open to debate is how to use this
drug. A reasonable approach might consider a short-
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administration and low cumulative exposure. Based on
this study, this could not be still sufficient to avoid toxic
effects, due to the possibility of an early toxicity. For this
reason, this therapy should be considered only by trying
to minimize risk for cardiotoxicity together with an
active strict monitoring strategy of treated individuals.
At present, this may be achieved by using personalized
therapeutic approaches using pharmacogenetics markers
[25] or by the use of analogues of MTX, like the
Pixantrone, which has been proposed as an alternative
possible therapy for MS patients with an active disease
not responding to current treatments [26].
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